{"name":"HUMA THERAPEUTICS LIMITED","company_number":"07725451","status":"Active","type":"Private Limited Company","incorporated":"2011-08-02","dissolved":null,"registered_office":"13th Floor Millbank Tower, 21-24 Millbank, London, England, SW1P 4QP","postcode":"SW1P 4QP","sic_codes":[{"code":61900,"description":"Other telecommunications activities"},{"code":62090,"description":"Other information technology service activities"}],"principal_activity":"The principal activities of the Group are the development and commercialisation of a technology platform that supports digital-first delivery of care and research. The Group serves three principal customer groups; triage, communication and remote patient monitoring for healthcare service providers; a platform to provide health tech solutions (Huma Cloud Platform) for the commercial divisions of life sciences companies; and solutions that support decentralised clinical trials for the R&D divisions of life sciences companies.","previous_names":[{"name":"HUMAFORHEALTH LIMITED","changed_on":"2020-04-17"},{"name":"MEDOPAD LTD","changed_on":"2020-04-16"}],"warnings":[],"accounts":{"category":"Group","year_end":"29 December","last_made_up_to":"2024-12-31","next_due":"2026-12-29"},"employees":{"count":67,"accounts_date":"2024-12-31"},"financials":[{"financial_date":"2024-12-31","profit_loss":-28780,"net_assets":103622,"cash":11933,"average_employees":67},{"financial_date":"2023-12-31","net_assets":103245,"cash":11549,"average_employees":84},{"financial_date":"2021-12-31"},{"financial_date":"2020-12-31"},{"financial_date":"2019-12-31","cash":10828}],"officers":{"current":4,"resigned":5,"complete":true,"note":"Names and details of individual officers are on the People page (subscriber-only on this site) and free at Companies House."},"charges":{"total":0,"outstanding":0},"gazette_notices":[],"insolvency_outcome":null,"ai_summary":"Huma Therapeutics is a top-tier UK digital health platform by revenue (£30.1m) with software-grade gross margins (~75%) and a rare positive-equity balance sheet, positioned as a consolidator in a sector still emerging from its post-2021 funding winter. Its pivot toward profitability is tracking ahead of loss-making peers (losses down 54%, opex down 46%), but thin cash cover, flat organic growth and two consecutive qualified audit opinions over revenue recognition leave the company's credibility and runway dependent on executing its guided 2025 EBITDA inflection and continued access to structured funding.","website":"https://www.huma.com/","links":{"page":"https://www.companiesintheuk.co.uk/ltd/huma-therapeutics","people":"https://www.companiesintheuk.co.uk/company/huma-therapeutics/people","filing_history":"https://www.companiesintheuk.co.uk/company/huma-therapeutics/filing-history","companies_house":"https://find-and-update.company-information.service.gov.uk/company/07725451","financials":"https://www.companiesintheuk.co.uk/company/huma-therapeutics/financial","control":"https://www.companiesintheuk.co.uk/company/huma-therapeutics/control","charges":"https://www.companiesintheuk.co.uk/company/huma-therapeutics/charges","ai_analysis":"https://www.companiesintheuk.co.uk/company/huma-therapeutics/analysis"},"source":"CompaniesInTheUK, from Companies House, The Gazette and other public registers (see /support/about). Cite as: CompaniesInTheUK, https://www.companiesintheuk.co.uk/ltd/huma-therapeutics"}